Skip to main content

Dr. Eric W. Schneider, MD

Retina Specialist (Retina Specialist (Ophthalmology) Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2008
Medicare patients seen, 2024
1,188

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Medical school: University of Michigan Medical School
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Retina Specialist (Ophthalmology) Physician primary
    TN license 51025 · KY license 47315
  • Ophthalmology Physician
    KY license 47315 · TN license 51025

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Retina Specialist per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,188
Services billed
42,131
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, faricimab-svoa, 0.1 mg13,98039
Injection, aflibercept, 1 mg3,254260
Imaging of retina2,987909
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg2,729153
Injection of drug into eye2,377490
Established patient complete exam of visual system1,849868
Injection, ranibizumab, 0.1 mg88585
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg64365
Photography of the retina549481
New patient office or other outpatient visit, 45-59 minutes231231

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 23 payments worth $12,472 in total to this clinician.

By type
Consulting Fee$11,645
Food and Beverage$827

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 19, 2025Regeneron Healthcare Solutions, Inc.
Sep 19, 2025
Consulting Fee
EYLEA; EYLEA HD · OPHTHALMOLOGY
$3,868
Sep 19, 2025Regeneron Healthcare Solutions, Inc.
Sep 19, 2025
Consulting Fee
EYLEA; EYLEA HD · OPHTHALMOLOGY
$3,315
Jul 9, 2025Regeneron Pharmaceuticals, Inc.
Jul 9, 2025
Consulting Fee
EYLEA HD · OPHTHALMOLOGY
$2,763
Sep 5, 2025Boehringer Ingelheim International GmbH
Sep 5, 2025
Consulting Fee$950
Sep 25, 2025Carl Zeiss Meditec, Inc.
Sep 25, 2025
Consulting Fee
QUATERA 700; CALLISTO eye; CIRRUS HD-OCT · Phaco / Vitrecomy
Company’s descriptionZeiss has contractual agreements with Healthcare Professionals and Organizations to consult, validate, or participate in research activities.
$750

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $2,799,205 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
    Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914
  • A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
    Boehringer Ingelheim International GmbH
  • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
    Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503
  • A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema
    Boehringer Ingelheim International GmbH
  • A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
    Astellas Pharma Global Development
  • A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1…
    Hoffmann-la Roche Limited
  • A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
    Boehringer Ingelheim International GmbH
  • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Retina Specialist clinicians in Nashville

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 4, 2017), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1790949485. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.